Skip to main content


Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease

Dry eyes
All genders
person-wave 18+
Recruiting now
More information  


Principal Investigator: Pedram Hamrah, MD

This prospective, single center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of IDI on ameliorating the signs and symptoms of dry eye disease. The study aims to enroll 54 patients (36 Dextenza commercial formulation, 18 Collagen Plug) with DED.

Study details

Inclusion Criteria
  • Symptoms of DED such as foreign body sensation, burning, itching, stinging for at least 6 months
  • Ocular Surface Disease Index (OSDI) score > 23
  • Two or more of the following objective signs:
    - Schirmer’s II test <10 mm at 5 minutes
    - Tear break-up time (TBUT) of <10 seconds in one eye
    - Corneal fluorescein staining of ≥4 (National Eye Institute grading scheme, 0-15) in at least one eye
    - Conjunctival lissamine green staining of the nasal and temporal conjunctiva ≥4 (National Eye Institute grading scheme, 0-18) in at least
    one eye
Exclusion Criteria
  • History of diabetes
  • History of ocular surgery, corneal infection, or corneal injury within the last 3 months
  • Active ocular allergies, ocular infection or allergies to benzalkonium chloride “BAK” (an eye-drop preservative)
Study Requirements

3 visits: Screening, Baseline (which can be combined) and a follow up visit 1 month after.

Jump back to top